<DOC>
	<DOCNO>NCT01186068</DOCNO>
	<brief_summary>The purpose study evaluate dose-response relationship ( effect ) four concentration V-101 Cream patient erythematous ( redness ) rosacea .</brief_summary>
	<brief_title>Dose Response Study Patients With Erythematous Rosacea</brief_title>
	<detailed_description>Patients must moderate severe erythematous ( facial redness ) rosacea - Male female patient must least 18 year old good general health - Female patient must pregnant nursing</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<criteria>male female least 18 year age diagnosis stable erythematous rosacea &lt; 3 inflammatory lesion good general health female must nonpregnant nonlactating must willing sign consent form ocular , phymatous type rosacea allergy ingredient study drug participation investigational study within 30 day enrollment use systemic steroid within 28 day Baseline use tetracycline antibiotic within 28 day baseline use product contain oxymetazoline within 14 day baseline use topical steroid witin treatment area 14 day prior baseline use Rx OTC product treatment acne rosacea within 14 day baseline use product reduce redness within treatment area witin 14 day prior baseline use monoamine oxidase ( MAO ) inhibitor use niacin &gt; /= 500mg/day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Rosacea , erythema</keyword>
</DOC>